◀ Back to MAPK3
MAPK3 — MYC
Pathways - manually collected, often from reviews:
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
Text-mined interactions from Literome
Whitwam et al., Oncogene 2007
(Cell Transformation, Neoplastic...) :
Although both NRAS and KRAS activate
mitogen activated protein kinase signaling, only NRAS
enhances MYC activity in these cells
Chang et al., Oncogene 2008
(Prostatic Neoplasms) :
C-Myc may also be
regulated at the protein level by
extracellular signal regulated kinase 1/2 and GSK3beta
Duan et al., Dig Dis Sci 2010
(Bile Duct Neoplasms...) :
Our results revealed that the specific
MAPK-ERK cascade inhibitor, PD98059, significantly
attenuated phosphorylation of
c-Myc on Ser-62 and FasL upregulation in QBC-939 cells and these cells showed decreased cytotoxicity against Fas-sensitive Jurkat T cells
Gramling et al., Cell Death Differ 2012
(Cell Transformation, Neoplastic...) :
We report the novel findings that
Myc alone
induced Ras/Mapk pathway signaling, and increased signaling following growth factor stimulation
Imran et al., Eur J Cancer 2012
:
These findings exhibit anticarcinogenic potential of TIS21 via downregulation of c-Myc expression during ATRA induced differentiation of HL-60 cells involving
activation and deactivation of two major
c-Myc regulators,
Erk1/2 and Akt, respectively